ATE522200T1 - Aripiprazole injektionsuspension - Google Patents
Aripiprazole injektionsuspensionInfo
- Publication number
- ATE522200T1 ATE522200T1 AT04779411T AT04779411T ATE522200T1 AT E522200 T1 ATE522200 T1 AT E522200T1 AT 04779411 T AT04779411 T AT 04779411T AT 04779411 T AT04779411 T AT 04779411T AT E522200 T1 ATE522200 T1 AT E522200T1
- Authority
- AT
- Austria
- Prior art keywords
- aripiprazole
- extended release
- injection suspension
- aripiprazole injection
- injection
- Prior art date
Links
- 229940025916 aripiprazole injection Drugs 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 238000013265 extended release Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 239000004005 microsphere Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229960004372 aripiprazole Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/635,221 US20050032811A1 (en) | 2003-08-06 | 2003-08-06 | Methods for administering aripiprazole |
PCT/US2004/024345 WO2005016262A2 (en) | 2003-08-06 | 2004-07-29 | Methods for administering aripiprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE522200T1 true ATE522200T1 (de) | 2011-09-15 |
Family
ID=34116189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04779411T ATE522200T1 (de) | 2003-08-06 | 2004-07-29 | Aripiprazole injektionsuspension |
Country Status (22)
Country | Link |
---|---|
US (9) | US20050032811A1 (de) |
EP (2) | EP2340810A1 (de) |
JP (3) | JP5300194B2 (de) |
CN (2) | CN102133171A (de) |
AT (1) | ATE522200T1 (de) |
AU (1) | AU2004264886C1 (de) |
CA (1) | CA2534997C (de) |
CY (1) | CY1111874T1 (de) |
DK (1) | DK1660037T3 (de) |
ES (1) | ES2369893T3 (de) |
HK (1) | HK1091725A1 (de) |
HR (1) | HRP20110646T1 (de) |
IL (1) | IL173441A (de) |
MX (1) | MXPA06001350A (de) |
NO (1) | NO339816B1 (de) |
NZ (1) | NZ545037A (de) |
PL (1) | PL1660037T3 (de) |
PT (1) | PT1660037E (de) |
SE (1) | SE1660037T5 (de) |
SI (1) | SI1660037T1 (de) |
WO (1) | WO2005016262A2 (de) |
ZA (1) | ZA200601385B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770478B2 (en) * | 2000-02-10 | 2004-08-03 | The Regents Of The University Of California | Erythrocytic cells and method for preserving cells |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
UA82561C2 (uk) | 2003-10-23 | 2008-04-25 | Оцука Фармасьютикалз Ко., Лтд. | Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії |
EP2279727A3 (de) * | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoteilchenförmige Aripiprazolformulierungen |
JP5401095B2 (ja) * | 2005-11-17 | 2014-01-29 | ゾゲニクス インコーポレーティッド | 無針注射による粘性製剤の送達方法 |
US7799790B2 (en) | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
EP1880714A1 (de) * | 2006-07-20 | 2008-01-23 | Helm AG | Amorphes Aripiprazol und Verfahren zu dessen Herstellung |
GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
KR101892745B1 (ko) * | 2007-06-25 | 2018-08-28 | 오쓰까 세이야꾸 가부시키가이샤 | 코어/셀 구조를 가진 미소구 |
EP2170279B1 (de) * | 2007-07-31 | 2017-12-27 | Otsuka Pharmaceutical Co., Ltd. | Verfahren zur herstellung einer aripiprazol-suspension und einer gefriergetrockneten formulierung |
US8686009B2 (en) | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
RS56352B2 (sr) * | 2009-06-25 | 2023-02-28 | Alkermes Pharma Ireland Ltd | Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja |
ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
EP2629775A4 (de) * | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | Injizierbare formulierung mit verzögerter freisetzung |
AR083884A1 (es) * | 2010-11-16 | 2013-03-27 | Otsuka Pharma Co Ltd | Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa |
CN102525915B (zh) * | 2010-12-14 | 2016-09-28 | 江苏豪森药业集团有限公司 | 一种持续释放的注射制剂及其制备方法和用途 |
LT3156056T (lt) * | 2011-03-18 | 2024-02-26 | Alkermes Pharma Ireland Limited | Farmacinės kompozicijos, apimančios sorbitano esterius |
JO3410B1 (ar) | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | تركيبة أريبيبرازول مجفف بالتبريد |
JP5952912B2 (ja) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | 二級アミン化合物のプロドラッグ |
CN103301461B (zh) * | 2012-03-08 | 2018-09-07 | 江苏豪森药业集团有限公司 | 一种长效注射制剂及其制备方法和用途 |
JP6333802B2 (ja) * | 2012-03-19 | 2018-05-30 | アルカームス ファーマ アイルランド リミテッド | ベンジルアルコールを含む医薬組成物 |
AU2013235519C1 (en) * | 2012-03-19 | 2018-04-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
EP2827867B1 (de) * | 2012-03-19 | 2019-11-06 | Alkermes Pharma Ireland Limited | Pharmazeutische zusammensetzungen mit glycerinestern |
AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
EP2897592B1 (de) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität |
US9051268B2 (en) | 2013-04-30 | 2015-06-09 | Otsuka Pharmaceutical Co., Ltd. | Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
CN106132415A (zh) * | 2014-03-20 | 2016-11-16 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
CN105078898B (zh) * | 2014-05-22 | 2018-08-28 | 上海现代药物制剂工程研究中心有限公司 | 阿立哌唑长效缓释微粒注射剂及其制备方法 |
BR112017002926A2 (pt) * | 2014-08-18 | 2017-12-12 | Alkermes Pharma Ireland Ltd | composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo |
PL3185867T3 (pl) | 2014-08-25 | 2021-11-22 | Alkermes Pharma Ireland Limited | Sposób krystalizacji pochodnych arypiprazolu w formulacjach o przedłużonym uwalnianiu do leczenia schizofrenii |
CN106474058B (zh) | 2015-08-31 | 2020-01-07 | 南京诺瑞特医药科技有限公司 | 具有延长的保质期的阿立哌唑可注射悬浮液制剂 |
EP3761983A1 (de) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Dosierstrategie für aripiprazol |
CN108498456B (zh) | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
US20230310417A1 (en) | 2020-03-30 | 2023-10-05 | Cipla Limited | Injectable aripiprazole formulation |
BR112022018721A2 (pt) | 2020-04-01 | 2022-11-01 | Otsuka Pharma Co Ltd | Métodos de administração de uma preparação injetável de aripiprazol |
CN115212174B (zh) * | 2022-07-18 | 2024-02-20 | 辉粒药业(苏州)有限公司 | 一种载阿立哌唑长效缓释微球及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5832899A (ja) * | 1981-08-18 | 1983-02-25 | Takeda Chem Ind Ltd | オキセンドロン水性懸濁剤 |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US7179486B1 (en) * | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
US6559128B1 (en) * | 2000-01-21 | 2003-05-06 | Northwestern University | Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US7071227B2 (en) * | 2000-09-26 | 2006-07-04 | The Johns Hopkins University | Antiviral compositions and methods of use |
DE10048868A1 (de) * | 2000-10-02 | 2002-04-11 | Basf Ag | Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter |
JP2002191256A (ja) | 2000-12-26 | 2002-07-09 | Yoshikatsu Nakajima | 水 槽 |
CN100350977C (zh) * | 2001-06-14 | 2007-11-28 | 大塚制药株式会社 | 药物组合物 |
WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
UA82561C2 (uk) * | 2003-10-23 | 2008-04-25 | Оцука Фармасьютикалз Ко., Лтд. | Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії |
-
2003
- 2003-08-06 US US10/635,221 patent/US20050032811A1/en not_active Abandoned
-
2004
- 2004-07-29 CN CN2011100063238A patent/CN102133171A/zh active Pending
- 2004-07-29 PT PT04779411T patent/PT1660037E/pt unknown
- 2004-07-29 PL PL04779411T patent/PL1660037T3/pl unknown
- 2004-07-29 CA CA2534997A patent/CA2534997C/en active Active
- 2004-07-29 SE SE04779411T patent/SE1660037T5/xx unknown
- 2004-07-29 MX MXPA06001350A patent/MXPA06001350A/es active IP Right Grant
- 2004-07-29 AU AU2004264886A patent/AU2004264886C1/en active Active
- 2004-07-29 NZ NZ545037A patent/NZ545037A/en unknown
- 2004-07-29 SI SI200431772T patent/SI1660037T1/sl unknown
- 2004-07-29 CN CNA2004800252878A patent/CN1845721A/zh active Pending
- 2004-07-29 JP JP2006522614A patent/JP5300194B2/ja active Active
- 2004-07-29 WO PCT/US2004/024345 patent/WO2005016262A2/en active IP Right Grant
- 2004-07-29 AT AT04779411T patent/ATE522200T1/de active
- 2004-07-29 DK DK04779411.0T patent/DK1660037T3/da active
- 2004-07-29 ES ES04779411T patent/ES2369893T3/es active Active
- 2004-07-29 EP EP10193459A patent/EP2340810A1/de not_active Withdrawn
- 2004-07-29 EP EP04779411A patent/EP1660037B1/de active Active
-
2006
- 2006-01-30 IL IL173441A patent/IL173441A/en active IP Right Grant
- 2006-02-09 NO NO20060638A patent/NO339816B1/no unknown
- 2006-02-16 ZA ZA200601385A patent/ZA200601385B/xx unknown
- 2006-11-07 HK HK06112238.1A patent/HK1091725A1/xx unknown
-
2008
- 2008-10-15 US US12/251,656 patent/US8338427B2/en active Active
-
2010
- 2010-08-02 JP JP2010173601A patent/JP5453194B2/ja active Active
-
2011
- 2011-09-07 HR HR20110646T patent/HRP20110646T1/hr unknown
- 2011-09-29 CY CY20111100940T patent/CY1111874T1/el unknown
-
2012
- 2012-03-15 US US13/420,822 patent/US8338428B2/en not_active Expired - Lifetime
- 2012-10-10 US US13/648,544 patent/US8759351B2/en not_active Expired - Lifetime
-
2013
- 2013-10-10 JP JP2013212864A patent/JP5764634B2/ja active Active
-
2014
- 2014-01-21 US US14/160,176 patent/US20140275109A1/en not_active Abandoned
-
2017
- 2017-08-02 US US15/666,840 patent/US20180169005A1/en not_active Abandoned
-
2018
- 2018-10-22 US US16/166,400 patent/US20190231679A1/en not_active Abandoned
-
2020
- 2020-12-21 US US17/247,708 patent/US20210346282A1/en not_active Abandoned
-
2023
- 2023-03-15 US US18/121,883 patent/US20230218506A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE522200T1 (de) | Aripiprazole injektionsuspension | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
BRPI0620063B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração | |
ATE450252T1 (de) | Arzneimittel-mikroteilchen | |
MY151468A (en) | Controlled release solid preparation | |
WO2006002365A3 (en) | Microparticles with high loadings of a bioactive agent | |
DE60205749D1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
UA88300C2 (ru) | Гидрогелевые композиции, которые содержат интерферон | |
DK1256343T3 (da) | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser | |
ATE432689T1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
HK1119596A1 (en) | Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases | |
EA200700484A1 (ru) | Фармацевтическая композиция толтеродина с пролонгированным высвобождением | |
IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product | |
BR0013283A (pt) | Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo | |
ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
ATE334658T1 (de) | Arzneimittel zur verabreichung an schleimhäute | |
EA200701525A1 (ru) | Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением | |
SE0203817D0 (sv) | New composition | |
BR0315231A (pt) | Compostos com base em glicose com afinidade para p-seletina | |
EA200701010A1 (ru) | Препарат гепирона с высокой дозировкой и длительным высвобождением | |
BRPI0510858A (pt) | composição, composto e método para administrar um agente biologicamente ativo a um animal necessitando o mesmo | |
ATE429905T1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1660037 Country of ref document: EP |